Gland Pharma has reported results for third quarter ended December 31, 2024 (Q3FY25)
The company has reported 6.62% rise in net profit at Rs 295.12 crore for Q3FY25 as compared to Rs 276.81 crore for the same quarter in the previous year. However, total income of the company decreased by 5.73% at Rs 1075.85 crore for Q3FY25 as compared to Rs 1141.25 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 6.69% rise in its net profit at Rs 204.69 crore for the quarter ended December 31, 2024 as compared to Rs 191.86 crore for the same quarter in the previous year. However, total income of the company decreased by 8.85% at Rs 1442.55 crore for Q3FY25 as compared to Rs 1582.55 crore for the corresponding quarter previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1693.15 |
| Dr. Reddys Lab | 1221.25 |
| Cipla | 1230.75 |
| Zydus Lifesciences | 939.20 |
| Lupin | 2326.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: